stock.name

Novo Nordisk - ADR

NVO

Market Cap$427.74B
Close$

Compare Novo Nordisk - ADR

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novo Nordisk - ADRNovo Nordisk - ADR00.82%---
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Earnings Call Q4 2023

January 31, 2024 - AI Summary

Novo Nordisk reported strong performance in 2023, with double-digit sales and operating profit growth.
The company made progress on its strategic aspirations, including reaching more than 40 million patients without diabetes and obesity treatments and expanding the number of women in senior leadership positions.
Sales growth was driven by both North America operations (54% growth) and international operations (15% growth).
GLP-1 sales in diabetes increased by 52%, driven by strong performance in both North America and international operations.
Obesity care sales grew significantly, with a 154% increase overall. Wegovy sales reached around DKK 2 billion, and the company plans to gradually increase supply throughout 2024.
Novo Nordisk expects sales growth between 18% and 26% at constant exchange rates in 2024, primarily driven by volume growth of GLP-1-based treatments for obesity and diabetes care. Operating profit is expected to grow between 21% and 29% at constant exchange rates. The company has also approved a new share repurchase program of up to DKK 20 billion for the next 12 months.
$128.04

Current Fair Value

6.9% upside

Undervalued by 6.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$427.74 Billion
Enterprise Value-
Dividend Yield$1.0256 (0.82%)
Earnings per Share$0.0
Beta0.55
Outstanding Shares3,435,128,000
Avg 30 Day Volume5,555,159

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio0.0
PEG-
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

ESG Score

No data

About Novo Nordisk

CEO: Lars Fruergaard Joergensen